Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder

Jul 12, 2014Journal of affective disorders

Quality of life improvements with 50mg desvenlafaxine compared to placebo in working adults with major depression

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a trial with 427 patients, desvenlafaxine treatment resulted in 46% of patients experiencing severe quality of life impairment compared to 62% for placebo.

Statistically significant improvements were observed in 10 of 16 quality of life scores for desvenlafaxine compared to placebo.
Patients treated with desvenlafaxine showed a lower percentage of severe quality of life impairment at week 12.
A strong correlation existed between changes in quality of life scores and changes in depression severity scores at week 12.
Improvements in depression severity at week 2 predicted greater changes in quality of life scores by week 12 for the desvenlafaxine group.

AI simplified

BACKGROUND: Diminished quality of life (QOL) is associated with major depressive disorder (MDD).

METHODS: QOL was assessed in a post-hoc analysis of a double-blind, placebo-controlled trial. Employed adult outpatients with MDD were randomly assigned to 12 weeks of treatment with desvenlafaxine 50mg/d or placebo. Changes from baseline in the Short Form of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) item scores at week 12 were analyzed using analysis of covariance with treatment, region, and baseline in the model. Correlations between change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score and Q-LES-Q scores were computed.

RESULTS: The intent-to-treat population included 427 patients. There were statistically significant improvements from baseline for desvenlafaxine vs placebo in 10 of 16 Q-LES-Q item scores (P values ≤0.0441). The percentage of patients with severe QOL impairment (≥2 SD below community norm) at week 12 was significantly lower for desvenlafaxine (46%) vs placebo (62%; P=0.0024; baseline: 95% and 94%, respectively). Change in Q-LES-Q total score was highly correlated with change in HAM-D17 score at week 12, LOCF (P<0.0001), and improvement in HAM-D17 total score at week 2 predicted change in Q-LES-Q total score at week 12 for the desvenlafaxine group (F=24.89; P<0.0001) but not placebo.

LIMITATIONS: This analysis excluded patients who were unemployed, had severe comorbidities, and those taking multiple, concomitant medications.

CONCLUSION: Improvement in QOL and depressive symptoms was significantly greater for employed depressed patients treated with desvenlafaxine vs placebo.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief